New hope in non-invasive cancer treatment
-
No Post Treatment Scars
Non-invasive therapy requires no incisions or needles, eliminating surgical wounds and significantly reducing infection risk, bleeding, and downtime.
-
Precise, Targeted Treatment
Advanced technology targets and destroys tumor tissue with precise accuracy, preserving surrounding organs and vital structures.
-
Faster Recovery Time
With no surgical trauma and minimal impact on healthy tissue, faster recovery, less discomfort, and a quicker return to normal life.
Find the right cancer treatment
MediChoice helps patients access non-invasive liver cancer treatment and clinical trials in Hong Kong. We match you instantly with the right hospitals and treatments — based on your diagnosis.
Even if you’re not eligible for non-invasive treatment, we help match you with ongoing clinical trials in Hong Kong & Asia.
Who Is Histotripsy Suitable For?
-
Early Stage (BCLC 0–A)
Ideal for small, localised liver tumors. Non-invasive option for patients seeking precise tumor destruction without surgery or heat.
-
Intermediate Stage (BCLC B / Multiple lesions)
Suitable for larger or multiple tumors when each lesion is safely targetable. Helps control tumor growth with minimal damage to healthy liver.
-
Advanced Stage With Vascular Invasion (BCLC C)
Can treat select advanced cases, including tumors with portal-vein or vascular invasion, if the target is accessible and liver function is stable.
-
Other Types of Cancer (Clinical Trials)
Histotripsy is now in clinical trials for multiple metastatic cancers, including breast and prostate.
3,478 Treatment Matches
MediChoice helped to find the right cancer treatment and clinical trials
Supported by
Hong Kong, the Asia-Pacific leader in non-invasive cancer treatment
-
Hong Kong Pioneers Multimodal Focal Therapy for…
Read moreHong Kong – In a significant medical breakthrough, The Chinese University of Hong Kong (CUHK) has established itself as a pioneer in Asia by introducing and systematically evaluating multimodality focal…
-
Li Ka Shing Foundation Brings Groundbreaking No…
Read moreHong Kong has made medical history as the first region in Asia to deploy cutting-edge histotripsy technology for liver cancer treatment, following a landmark donation from the Li Ka Shing...
-
Hong Kong Establishes itself as Asian Pioneer i…
Read moreHONG KONG – Hong Kong has solidified its position as Asia’s leading center for innovative non-invasive cancer treatment, becoming the first region in Asia to deploy revolutionary Histotripsy technology for clinical…
“MediChoice helped me when I was looking for non-invasive liver treatment. I didn't know Hong Kong already had this treatment available. And they helped me find the right Hospital for me.”
“I wasn’t sure which hospital to trust, but MediChoice matched me with the right specialist within a day. The process was smooth and stress-free.”
“I used MediChoice to check my eligibility for histotripsy. The team was professional, transparent, and helped me understand every part of the treatment journey.”
"Histotripsy is not available in my country, so I wanted help to select the right option and feel safe to travel to a new country to get the treatment. I relied on MediChoice to help me select the right place.”
